Cysteine proteinases in tumor cell growth and apoptosis: Minireview

Neoplasma

Volumn 48, Issue 5, 2001, Pages 332-349

  Krepela E ^a  

^a UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

Antitumor therapy; Caspase; Cathepsin; Cysteine proteinase; Tumor cell apoptosis; Tumor cell growth

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 7; CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE; ENZYME PRECURSOR;

APOPTOSIS; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; HUMAN; METASTASIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 0035206434     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (277)

1. Cathepsin B activity regulation heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation
2. Human ICE/CED-3 protease nomenclature
3. Granzyme B directly efficiently cleaves several downstream caspase substrates: Implications for CTL-induced apoptosis
4. Binding of perforin to membranes is sensitive to lipid spacing and not headgroup
5. Enzymatic reduction of disulfide bonds in lysosomes: Characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT)
6. Safety and antitumor activity of recombinant soluble Apo2 ligand
7. Inhibition of extracellular matrix-degrading endopeptidases: Problems, comments and hypotheses
8. Genetic analysis of the APAF1 gene in male germ cell tumors
9. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid
10. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the apaf-1 apoptosome
11. Expression and functional analysis of Apaf-1 isoforms - Extra WD-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9
12. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
13. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway
14. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
15. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells
16. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions
17. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells
18. Ubiquitin-mediated degradation of the proapoptotic active form of Bid. A functional consequence on apoptosis induction
19. Cytosolic delivery of granzyme B by bacterial toxins: Evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin
20. Hsp27 negatively regulates cell death by interacting with cytochrome c
21. Oxidative stress, growth factor starvation and Fas activation may all cause apoptosis through lysosomal leak
22. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues
23. Cathepsin K expression in human lung
24. CA074 methyl ester: A proinhibitor for intracellular cathepsin B
25. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement
26. Apaf-1 oligomerizes into biologically active ∼700-kDa and inactive ∼1.4-MDa apoptosome complexes
27. Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy
28. Regulation of cell death protease caspase-9 by phosphorylation
29. Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas
30. Structural and biochemical basis of apoptotic activation by Smac/DIABLO
31. Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver
32. Cloning, isolation and characterization of mammalian legumain, an asparaginyl endopeptidase
33. Conversion of Bcl-2 to a Bax-like death effector by caspases
34. Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases
35. Initiation of Apaf-1 translation by internal ribosome entry
36. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions
37. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C
38. Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C
39. In vitro activation of pro-cathepsin B by three serine proteinases: Leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator
40. Competition between plasminogen and procathepsin B as a probe to demonstrate the in vitro activation of procathepsin B by the tissue plasminogen activator
41. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage
42. Mature cathepsin L is substantially active in the ionic milieu of the extracellular medium
43. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1
44. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases
45. IAP family proteins - Suppressors of apoptosis
46. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
47. X-linked lAP is a direct inhibitor of cell-death proteases
48. Endostatin induces endothelial cell apoptosis
49. Nitric oxide inhibits APO-1/Fas-mediated cell death
50. Human colon cancer cells express the functional Fas ligand
51. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma
52. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
53. Mammalian caspases: Structure, activation, substrates and functions during apoptosis
54. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation
55. Clearance: The last and often forgotten stage of apoptosis
56. A receptor for phosphatidylserine-specific clearance of apoptotic cells
57. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts
58. Caspases disrupt the nuclear-cytoplasmic barrier
59. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis
60. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
61. Secreted cathepsin L generates endostatin from collagen XVIII
62. Matrilysin in early stage intestinal tumorigenesis
63. Evidence for a function of death-receptor-related, death-domain-containing proteins in anoikis
64. Molecular regulation, membrane association and secretion of tumor cathepsin B
65. Nitric oxide synthase activity in human lung cancer
66. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases
67. Apoptosis induced by granzyme B-glycosaminoglycan complexes: Implications for granule-mediated apoptosis in vivo
68. The collagenolytic activity of cathepsin K is unique among mammalian proteinases
69. Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines
70. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate
71. Adhesion and apoptosis
72. Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms
73. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant
74. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L
75. TRAIL: A molecule with multiple receptors and control mechanisms
76. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL
77. Protein sorting and secretion during CTL killing
78. Killing mechanisms of cytotoxic T lymphocytes
79. Caspase cleaved Bid targets mitochondria and is required for cytochrome c release, while BCL-X-L prevents this release but not tumor necrosis factor-R1/Fas death
80. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
81. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c
82. "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin
83. The hallmarks of cancer
84. Apoptotic protease activating factor 1 (Apaf-1)-independent cell death suppression by Bcl-2
85. Pro-apoptotic apoptosis protease-activating factor 1(Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x(L)
86. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members Bid and Bax
87. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines
88. Secretion of a latent, acid activatable cathepsin L precursor by human non-small cell lung cancer cell lines
89. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant benign human breast tumors
90. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: Role of La autoantigen in XIAP translation
91. Translational up-regulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death
92. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
93. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation apoptosis
94. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma
95. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma
96. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis
97. Inhibition of death receptor signals by cellular FLIP
98. Processing and functions of procathepsin L
99. Gene regulation and extracellular functions of procathepsin L
100. Activation of caspase-3 by lysosomal cysteine proteases and its role in 2,2′-azobis-(2-amidinopropane) dihydrochloride (AAPH)-induced apoptosis in HL-60 Cells
101. Participation of a cathepsin L-type protease in the activation of caspase-3
102. Activation of caspase-3-like protease by digitonin-treated lysosomes
103. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis
104. ATP-activated oligomerization as a mechanism for apoptosis regulation: Fold and mechanism prediction for CED-4
105. Resistance of cytolytic lymphocytes to perforin-mediated killing. Inhibition of perforin binding activity by surface membrane proteins
106. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1
107. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
108. Cystatin a expression reduces bile salt-induced apoptosis in a rat hepatoma cell line
109. Differences in expression of pro-caspases in small cell non-small cell lung carcinoma
110. FADD is required for multiple signaling events downstream of the receptor Fas
111. Proteinase inhibitor 9, an inhibitor of granzyme B-mediated apoptosis, is a primary estrogen-inducible gene in human liver cells
112. Livin a novel inhibitor-of-apoptosis (IAP) family member
113. A novel procaspase-3 activating cascade in liver lysosomes, and lack of the cascade in hepatoma cells
114. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
115. Determinants of the apoptotic response to lysosomal photodamage
116. Role for Bcl-xL as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis
117. Retention of cell adhesion and growth capability in human cervical cancer cells deprived of cell anchorage
118. Molecular determinants of response to TRAIL in killing of normal cancer cells
119. Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8
120. Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells
121. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
122. Matrix metalloproteinases and metastasis
123. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA)
124. Unraveling the role of proteases in cancer
125. Disassembly of genome of higher eukaryotes: Pulsed-field gel electrophoretic study of initial stages of chromatin and DNA degradation in rat liver and thymus nuclei by VM-26 selected proteases
126. Demonstration of proteinase inhibitors cystatin A, B and C in breast cancer and in cell lines MCF-7 and ZR-75-1
127. Dead or dying: Necrosis versus apoptosis in caspase-deficient human renal cell carcinoma
128. Inhibition of tumour cell invasion by protease inhibitors: Correlation with the protease profile
129. Retroviral transfer of CPP32 beta gene into malignant gliomas in vitro and in vivo
130. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer
131. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
132. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease
133. Release of caspase-9 from mitochondria during neuronal apoptosis cerebral ischemia
134. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line
135. Different efficiency of proteolytic cleavage of histones by cathepsin B
136. Regulation of cathepsin B activity by cysteine related and related thiols
137. Cysteine proteases cysteine protease inhibitors in non-small cell lung cancer
138. Procaspase-3 expression and activation in non-small cell leng carcinoma
139. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers
140. Immunohistochemical analysis of Fas ligand expression in normal human tissues
141. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer
142. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells
143. Protease inhibitors: Current status and future prospects
144. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis
145. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation
146. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates
147. Induction of cell death by the lysosomotropic detergent MSDH
148. Exocytosis of active cathepsin B - Enzyme activity at pH 7.0, inhibition and molecular mass
149. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma
150. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis
151. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
152. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells
153. The caspase-3 precursor has a cytosolic and mitochondrial distribution: Implications for apoptotic signaling
154. Redistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosis
155. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
156. Fas-induced caspase denitrosylation
157. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
158. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage
159. Activation of multiple interleukin-1 β converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis
160. Caspases disrupt mitochondrial membrane barrier function
161. Elastinolytic activity of human cathepsin L
162. Surface activation of pro-cathepsin L
163. Procaspase-3 and poly(ADP)ribose polymerase (PARP) are calpain substrates
164. An auxiliary mode of apoptotic DNA fragmentation provided by phagocytes
165. Autocatalytic activation of human cathepsin K
166. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
167. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis
168. Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro
169. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism
170. Resistance of CTL to perforin-mediated lysis. Evidence for a lymphocyte membrane protein interacting with perforin
171. Mechanisms for pro matrix metalloproteinase activation
172. Physiological mechanisms for metalloproteinase activation
173. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
174. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens
175. An induced proximity model for caspase-8 activation
176. Activation mechanisms of matrix metalloproteinases
177. High levels of expression and nuclear localization of interleukin-1 β converting enzyme (ICE) and CPP32 in favorable human neuroblastomas
178. APO2L/TRAIL expression in human brain tumors
179. Lack of cell surface Fas/APO-1 β expression in pulmonary adenocarcinomas
180. Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins
181. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor
182. Caspase structure, proteolytic substrates, and function during apoptotic cell death
183. Human lung carcinomas express Fas ligand
184. Role of macrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells
185. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression
186. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance
187. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90
188. Dipeptidyl peptidase I is required for the processing and activation of granzimes A and B in vivo
189. The role of Apaf-1, caspase-9, and Bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis
190. Nuclear translocation of granzyme B in target cell apoptosis
191. Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis
192. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
193. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
194. Stoichiometry, free energy, and kinetic aspects of cytochrome c: Apaf-1 binding in apoptosis
195. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1
196. Bcl-2 family proteins
197. Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas
198. Nuclear localization of procaspase-9 and processing by a caspase-3-like activity in mammary epithelial cells
199. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes
200. Cathepsin D in cancer metastasis: A protease and a ligand
201. Caspase-9 and APAF-1 form an active holoenzyme
202. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
203. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process
204. Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: Inhibition by PKB/Akt but not Raf signalling
205. Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis
206. Acinus is a caspase-3- activated protein required for apoptotic chromatin condensation
207. Apoptosis: Definition, mechanisms, and relevance to disease
208. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation
209. Negative regulation of the Apaf-1 apoptosome by Hsp70
210. Caspase activation: The induced-proximity model
211. Apoptosis: Cell death defined by caspase activation
212. The pattern of CPP32/caspase-3 expression reflects the biological behavior of the human pancreatic duct cell tumors
213. Two CD95 (APO-1/Fas) signaling pathways
214. The role of c-FLIP in modulation of CD95- induced apoptosis
215. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
216. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: A kinetic analysis
217. Differences between CD95 type I and type II cells detected with the CD95 ligand
218. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down-regulation of its proapoptotic activity and loss of liver toxicity
219. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: Implication for gene therapy
220. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
221. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases -2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
222. Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I
223. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer
224. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
225. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization
226. Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE- like cysteine proteases
227. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis
228. Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits
229. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway
230. The Ced-3/interleukin 1β converting enzyme- like homolog Mch6 and the lamin-cleaving enzyme Mch2α are substrates for the apoptotic mediator CPP32
231. Caspase-9 can be activated without proteolytic processing
232. Pro-caspane-3 is a major physiologic target of caspase-8
233. Biochemical characteristics of caspases-3, -6, -7, and -8
234. Catalytic properties of the caspases
235. Caspases - Controlling intracellular signals by protease zymogen activation
236. Lysosomal protease pathways to apoptosis. Cleavage of Bid, not pro-caspases, is the most likely route
237. Mitochondrial release of caspase-2 and -9 during the apoptotic process
238. Initiation of apoptosis by granzyme B requires direct cleavage of Bid, but not direct granzyme B-mediated caspase activation
239. Functional absence of FADD in PLC/PRF/5 hepatoma cells: Possible involvement in the transformation to hepatoma in HBV-infected hepatocytes
240. Growth factors in the extracellular matrix
241. A single BIR domain of XIAP sufficient for inhibiting caspases
242. Angiodestruction and tissue necrosis of skin-involving CD56+NK/T-cell lymphoma are influenced by expression of cell adhesion molecules and cytotoxic granule and apoptosis-related proteins
243. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias
244. Downregulation of Fas ligand by shedding
245. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
246. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis
247. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins
248. Lysosomal cysteine proteases: More than scavengers
249. Apoptosis in gallbladder carcinomas and dysplasias, its relation to the expression of caspases 3, 6 and 8 and apoptosis regulating proteins Bcl- 2, Mcl-1 and Bax
250. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain
251. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion
252. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity
253. Identification of a new caspase homologue: Caspase-14
254. Tumor necrosis factor-related apoptosis- inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
255. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
256. NK cells and apoptosis
257. Cell detachment and metastasis
258. Identification and characterization of a new member of the TNF family that induces apoptosis
259. Caspase-3 and inhibitor of apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian cells
260. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast
261. Cancer gene therapy using a pro-apoptotic gene, caspase-3
262. Frameshift mutations in Fas, Apaf-1, and Bcl-10 in gastro-intestinal cancer of the microsatellite mutator phenotype
263. Perforin and granzyme expression in cytotoxic T-cell lymphomas
264. Cathepsin B and human tumor progression
265. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli
266. Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7
267. Essential role of active nuclear transport in apoptosis
268. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors
269. Mass spectrometric analysis of nitric oxide-modified caspase-3
270. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
271. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
272. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types
273. Caspases: Their intracellular localization and translocation during apoptosis
274. Solution structure of Apaf-1 CARD and its interaction with caspase-9 CARD: A structural basis for specific adaptor/caspase interaction
275. Activation of pro-caspase-7 by serine proteases includes a non-canonical specificity
276. Target protease specificity of the viral serpin CrmA. Analysis of five caspases
277. An Apaf-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9